

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Cutia Therapeutics**

**科笛集团**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2487)**

## **VOLUNTARY ANNOUNCEMENT**

### **INCREASE IN SHAREHOLDING BY THE CHIEF FINANCIAL OFFICER AND EXECUTIVE DIRECTOR**

This announcement is made by Cutia Therapeutics (the “**Company**”) on a voluntary basis to inform shareholders and potential investors of the Company in relation to the increase in shareholding in the Company by Mr. Huang Yuqing (“**Mr. Huang**”), the chief financial officer and executive director of the Company.

The board of directors (the “**Board**”) of the Company was informed by Mr. Huang that he purchased a total of 50,000 shares of the Company (the “**Share(s)**”) in the open market with his personal funds on 2 and 3 October 2024 for an aggregate consideration of approximately HK\$747,684 (the “**Shareholding Increase**”), representing an average price of approximately HK\$14.954 per Share.

Mr. Huang has expressed that the Shareholding Increase reflects his full confidence in the Company’s business outlook and prospects. Subject to compliance with applicable laws and regulatory requirements, Mr. Huang will not rule out the possibility of further increasing his shareholdings in the Company as and when appropriate.

Based on the information available to the Company and to the best knowledge of the Board, the Company has continued to maintain sufficient public float of the issued Shares in compliance with The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited immediately following the Shareholding Increase and as at the date of this announcement.

**Warning:** Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**Cutia Therapeutics**  
**Zhang Lele**  
*Chief Executive Officer and Executive Director*

Hong Kong, 8 October 2024

*As at the date of this announcement, the Board comprises (i) Ms. Zhang Lele and Mr. Huang Yuqing as executive directors; (ii) Dr. Chen Lian Yong, Dr. Xie Qin, Dr. Huang Xiao and Ms. Yang Yunxia as non-executive directors; and (iii) Mr. Chung Ming Kit, Mr. Tao Tak Yan Dennis and Mr. Ye Xiaoxiang as independent non-executive directors.*